Selventa Strengthens Intellectual Property for SysDx™ Approach to Personalized Medicine
News May 09, 2013
“We are very pleased to gain this important intellectual property protection that strengthens our SysDx approach to understanding a patient’s disease and predicting response or non-response to a therapy,” said David de Graaf, CEO of Selventa. “This patent is a significant step forward in the development of SysDx tests in multi-factorial diseases such as rheumatoid arthritis, IBD, and cancer. It also strengthens our leadership position in analyzing ‘big data’ molecular information to identify patient disease-relevant biomarkers.”
A major differentiator of SysDx tests is their ability to incorporate and analyze ALL relevant molecular information in a disease, across thousands of patients, to identify biomarkers that are linked to disease-driving mechanisms.
“In order to deliver true personalized medicine, physicians will require diagnostics that holistically integrate and interpret multiple types of biological data. SysDx tests consist of biomarkers that are selected through a rigorous biomarker analysis of a patient’s biological map derived from large, multi-omic data sets that can include genomic, epigenomic, transcriptomic, proteomic, metabolomic, electronic medial record information. This comprehensive analysis is then used to generate a clinically-relevant diagnostic report that physicians and patients can use to make an optimal treatment decision,” concluded de Graaf.
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
12th Edition of International Conference on Infectious Diseases
Apr 22 - Apr 23, 2019